epithalon

russian longevity peptide. one lab. one cohort. the lifespan claims have never been replicated.

tier C · focus · Russia Khavinson '80s

verdict

Russian longevity peptide. one lab (Khavinson). one human cohort (2003). the lifespan claims have never been replicated.

if you're asking about the telomerase / lifespan story — the telomerase activation data is from one lab. the human lifespan claim rests on a single Khavinson 2003 cohort that wasn't blinded and has never been independently replicated in the West. the rodent lifespan data is from the same lab. the gap between 'modest sleep-related effect, plausibly placebo-amplified' and 'human lifespan extension via telomerase activation' is where the C-tier sits.

if you're asking about the sleep / melatonin angle — community users report sleep and subjective mood improvements compatible with the pineal-melatonin-adjacent mechanism. that's the most consistent reported effect. clinical effects on melatonin and sleep are biologically plausible given the pineal lineage but poorly characterized in humans. cheap, easy to discuss, modest safety signals from limited community adoption.

if you came in worried about safety signals — the real safety gap is what hasn't been tested: no formal toxicology, genotoxicity, or carcinogenicity studies exist, and telomerase activation sits close to cancer biology in theory. the animal tumor data that does exist actually runs the other way, less colon carcinogenesis, less leukemia, fewer chromosome aberrations, though it all comes from the originating lab. the long-term safety record is not strong enough for the lifespan-marketing tone. FDA pulled epitalon from 503A category 2 in April 2026 with PCAC consultation scheduled for July. that's regulatory acknowledgement that it's been used, not validation that it works.

based on published evidence and disclosed clinical practice. not medical advice.

why C-tier

C-tier because the biology is plausible but the marketing has badly outrun the evidence. A real peptide from a real research program, with some mechanistic basis in pineal signaling and melatonin modulation. But the commercial sales pitch, telomerase activation and human lifespan extension, is the overreach. Single-lab data, single-cohort clinical trial, no Western replication. Community reports a sleep benefit that's probably real, but that's a much smaller claim than what vendors sell the compound on. Moves to B-tier only if independent replication of the telomerase or lifespan claims appears.

the core tension

Epithalon has an interesting pedigree: developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, based on a real pineal-gland peptide (epithalamin) that modulates melatonin. The problem is that the commercial story, "telomerase activator that extends human lifespan", comes almost entirely from one lab, one long-running Russian trial cohort, and rodent studies that haven't been replicated outside the original group. The pharmacology around pineal function and melatonin is plausible. The longevity claims are the overreach.

what it is

epithalon (also spelled epitalon) is a synthetic tetrapeptide, alanine-glutamate-aspartate-glycine, designed as a simplified analog of epithalamin, a pineal-gland peptide extract studied by Vladimir Khavinson's group in St. Petersburg since the 1970s. plasma half-life is minutes. CAS 307297-39-8.

what it does

in cultured cells from the Khavinson lab, upregulates telomerase and lengthens telomeres. in rodent studies from the same lab, modestly extends median and maximum lifespan. one Khavinson human cohort (2003) reported reduced all-cause mortality in elderly Russian subjects over multi-year administration. clinical effects on melatonin and sleep are biologically plausible given the pineal lineage but poorly characterized in humans.

origin

developed at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s and 90s. the entire research program, mechanism, animal data, and the single cited human cohort, comes from one institution. the same group's rodent cancer studies actually found epitalon lowered tumor burden, so the 'telomerase is one-way good' worry stays theoretical, not something the animal data has shown.

why researchers are interested

community users report sleep and subjective mood improvements compatible with the melatonin-adjacent mechanism. cheap, easy to discuss, and backed by an odd pineal-biology pedigree that is genuinely interesting science. the long-term safety record is not strong enough for the lifespan-marketing tone.

does it work

the longevity peptide space is dominated by Russian-only Khavinson research and industry press. epithalon is the clearest example. the telomerase activation data is from one lab. the human lifespan claim rests on a single 2003 cohort that wasn't blinded and has never been independently replicated in the West. the missing formal safety testing, no toxicology or carcinogenicity studies, is rarely mentioned in vendor copy. probable real effect: modest, sleep-related, plausibly placebo-amplified. claimed effect: human lifespan extension via telomerase activation. the gap between the two is where the C-tier sits. the FDA pulled epitalon from 503A category 2 in April 2026 with PCAC consultation scheduled for July; that's regulatory acknowledgement, not validation.

claims vs the data

• activates telomerase in human cells — weak — Khavinson lab has published telomerase-activation data in cultured cells. Independent replication is limited. Most commercial marketing presents this as established fact; the evidence base is one research group.
• extends lifespan in elderly humans — overreach — The foundational claim traces to a single Khavinson cohort study (2003) reporting mortality reduction in elderly Russian subjects. Single center, not blinded by modern standards, not replicated. Presented in commercial contexts as 'proven lifespan extension', which the evidence does not support.
• modulates melatonin rhythms — partially true — Plausible given the peptide's origin as an epithalamin analog, and some animal data supports pineal modulation. Clinical effects on melatonin in humans are not well-characterized outside the Khavinson group's own reports.
• improves sleep quality — partially true — Community reports are consistent enough that the sleep effect is probably real, and the melatonin-adjacent mechanism makes it biologically plausible. Not backed by Western clinical trials.
• reduces markers of biological aging — unverified — Scattered claims in Russian literature reporting effects on various aging biomarkers. No rigorous Western trials. No consensus on what a meaningful change in such markers would even mean clinically.

key facts

• molecular formula: C14H22N4O9
• molecular weight: 390.35 Da
• amino acids: 4
• half-life: minutes in plasma; downstream effects on melatonin signaling persist longer
• type: synthetic tetrapeptide (analog of pineal-gland peptide epithalamin)
• CAS: 307297-39-8
• 1 primary human clinical cohort (Khavinson, 2003)
• 1980s Khavinson's original pineal research program
• 0 FDA approvals for any indication
• 0 Western replication of lifespan claims

frequently asked questions

What is epithalon?

Epithalon (also spelled epitalon) is a synthetic tetrapeptide (Alanine-Glutamic acid-Aspartic acid-Glycine) developed by Vladimir Khavinson in Russia in the 1980s. It was designed as a bioactive fragment of epithalamin, a pineal gland extract.

What does epithalon do?

Preclinical and Khavinson-network clinical literature suggests epithalon may activate telomerase, the enzyme that maintains telomere length. Community users report longevity-oriented effects, improved sleep quality, circadian regulation, and general vitality over months of use. Western clinical evidence remains limited.

How is epithalon typically administered?

Russian gerontology literature used course-based administration in studied cohorts, but there is no FDA-approved dosing protocol and U.S. products are not approved medicines. Research peptide community patterns vary widely.

What are the side effects of epithalon?

Reported side effects are usually mild, especially injection-site reactions. The hard question is not acute tolerability, it is long-term safety around telomerase and cancer-biology claims. The Russian gerontology record is not the same thing as broad Western long-term validation.

Is epithalon FDA approved?

No. Epithalon has no FDA approval. It is a synthetic AEDG tetrapeptide developed from the epithalamin research lineage, but epithalamin is a separate pineal extract story. U.S. regulatory discussion concerns 503A compounding review, not approval.

How much does epithalon cost?

No US clinical retail price. On the research-chemical market it is inexpensive, reflecting its short 4-amino-acid length.

related peptides

• pinealon — sister peptide from the same Khavinson lab
• NAD+ — other longevity-positioned compound with stronger evidence base
• mots-c — mitochondrial peptide running a more rigorous longevity thesis

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.